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Background: Brain tumor remains the leading cause of disease-related death in children. Many studies have
focused on the complex biological process involved in pediatric brain tumors but little is know about the possible
role of microRNAs in the genesis of these tumors.
Methods: In this study, we used a microRNA microarray assay to study the expression pattern of microRNAs in
pediatric gliomas and matched normal tissues.
Results: We found 40 differentially expressed microRNAs, among which miR-1321, miR-513b, miR-769-3p were
found be related to cancer genesis for the first time. The expression of selected microRNAs were then confirmed by
qRT-PCR. Furthermore, GO and pathway analysis showed that the target genes of the 40 differentially expressed
microRNAs were significantly enriched in nervous system-related and tumor-related biological processes and
signaling pathways. Additionally, an apoptosis-related network of microRNA–mRNA interaction, representing the
critical microRNAs and their targets, was constructed based on microRNA status.
Conclusions: In the present study we identified the changed expression pattern of microRNAs in pediatric gliamas.
Our study also provides a better understanding of pediatric brain tumor biology and may assist in the development
of less toxic therapies and in the search for better markers for disease stratification.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1323049861105720
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Brain tumor, together with leukaemia, remains the leading
cause of disease-related death in children [1]. According
to a population-based study by Kaatsch and colleagues [2],
approximately 60% of pediatric brain tumors are gliomas.
Glioma is the most common type of primary brain tumor.
Brain glioma can cause headaches, nausea and vomiting,
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reproduction in any medium, provided the orincreased intracranial pressure. Based on the observations
that different gliomas share morphological similarities in
different lineages of glial cells, the respective tumors have
been classified as astrocytomas, oligodendrogliomas, and
ependymomas [3]. However, because the pathogenesis of
these tumors is unclear, treatment is particularly complex.
Many children who have been treated for brain tumors ex-
perience significant long-term problems, such as changes
in intellectual and motor function [4]. A better under-
standing of pediatric brain tumor pathogenesis is neces-
sary to provide better markers for disease stratification
and to assist in the development of less toxic therapies.
Aberrant microRNA expression has been found to be
associated with a wide variety of human tumors, including
lung cancer [5], cervical cancer [6], bladder cancer [7],
esophageal adenocarcinoma [8] and pituitary adenomas [9]
et al. MicroRNAs also play a significant role in brain tumorThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Liu et al. Diagnostic Pathology 2013, 8:158 Page 2 of 10
http://www.diagnosticpathology.org/content/8/1/158pathology by regulating target gene expression, apoptosis
and autophagy [10]. The expression of miR-21 has been
found to be increased between 5 and 100-fold in human
glioblastoma tissues compared to control non-neoplastic
brains [11]. A set of brain-enriched microRNAs, miR-128,
miR-181a, miR-181b and miR-181c have been found to be
down-regulated in glioblastoma [12]. Bottoni and his col-
leagues, using Northern blot, found that two microRNAs,
miR-15a and miR-16-1 had a reduced expression in pituit-
ary adenomas as compared to normal pituitary tissue [13].
Upregulation of mir-372 has also been found to be related
with poor prognosis in glioma [14].
Large profiling studies using solid tissue and hemato-
logical tumors have established the usefulness of microRNA
profiling for diagnosis and prognosis [15]. We therefore
sought to determine the expression profiles of microRNAs
in pediatric gliomas and matched normal tissues using
microRNAs microarrays. We also performed Gene Ontol-
ogy (GO) and pathway analysis to investigate the changed




For the study we recruited 8 patients undergoing surgery to
treat astrocytomas at the XinHua Hospital. During surgery
the tumor tissue and the matched adjacent noncancerous
tissues were cut into small pieces and stored in liquid nitro-
gen. The tissues collected in XinHua Hospital were kept
at −70°C until shipment to the Institute for Nutritional
Sciences for RNA extraction and other experiments. Writ-
ten informed consent was obtained from all patients or
their representatives, and the Shanghai Committee of hu-
man rights approved the study. The general information
of the tumor samples was summarized in Table 1.
MicroRNA microarray assay
Total RNA extraction and amplification
All of the RNA samples were extracted from tissues using
the Trizol (Life technology) method. DNase I (New EnglandTable 1 General information of the tumor samples
involved in the present study
No. Patient No. Gender Age Grade
1 666088 M 4-year-old WHO grade II
2 663136 M 2-year-old WHO grade II-III
3 698211 F 4-year-old WHO grade II
4 703380 M 1-year-old WHO grade I-II
5 655390 M 12-year-old WHO grade IV
6 688551 F 7-month-old WHO grade IV
7 709578 M 10-month-old WHO grade II-III
8 687901 M 5-year-old WHO grade IIBiolabs) was then added to digest the residual RNA.
After purification, the concentration was measured using
Nanodrop2000, all total RNA was reversely transcribed to
cDNA using a MessageAmp™ II aRNA Amplification Kit
(Ambion). T7 Enzyme Mix (Life technology) was then
used to perform transcription of cDNAs to aRNAs
in vitro. The linear amplified aRNAs were labeled using
dissolved Mono-functional CyDye (Cy5) and purified by
resin column.
Fluorescence labeling, hybridization and scanning
Firstly, microRNA probes (a total of 866 human micro-
RNAs; miRBase, release 12.0) printed on the microRNA
microarray (LC Sciences) were denatured at 95°C for 5
minutes. The microarray and probes were then hybrid-
ized with the Cy5-labeled aRNAs in the last step for 16
hours at 50°C. Next, 2X SSC + 0.2% SDS, 0.1% × SSC +
0.2% SDS, 0.1% × SSC (Amresco) were each used con-
secutively for ten minutes to wash the microarray. The
microarray was then scanned and fluorescence signals
were assessed.
Microarray data analysis
Data generated from the microarray was imported to
Microsoft Excel. After normalizing the signal of each
microRNA by using global average normalization as de-
scribed by Bilban et al. [16], the expression level of each
microRNA was calculated and student’s t test was per-
formed to estimate between-group differences. For each
microRNA, the difference between brain tumor and the
matched adjacent noncancerous tissues was set to be
significant if the fold change > 1.5 or < 0.67 and the p-
value < 0.05.
Quantitative RT-PCR analysis
Three of the up-regulated microRNAs, miR-1259, miR-21
and miR-222 and one of the down-regulated microRNAs,
miR-128, were selected at representatives for verification.
MiR-1259 and miR-128 exhibited lowest p-values, miR-21
was a well-known Onco-miR and miR-222 expression was
also proved to be related with the development of a variety
of tumors [17-20]. Expression of these microRNAs was
assayed using stem-loop RT followed by PCR analysis as
previously described (qRT-PCR) [21]. Real-time PCR was
performed using TaqMan PCR kit (Life technology) on an
Applied Biosystems 7900 Fast Real-Time PCR System
(Applied Biosystems). In our study, qRT-PCR was per-
formed in triplicate for each sample. The relative amount
of microRNAs was normalized against U6 snRNA, the sta-
bility value of which was 0.046 according to Normfinder
(http://www.multid.se/genex/hs410.htm). The fold change
for each microRNA was calculated using the 2-[delta][delta]
Ct method [22].
Table 2 Characteristics of microRNAs that were significantly up- or down-regulated in pediatric brain tumors
MicroRNA P-value FDR Fold change Genomic location Strand Region
Up-regulated microRNAs
hsa-miR-363* 0.007497 0.010704 10.427700 ChrX: 133303408-133303482 - Intergenic
hsa-miR-181b 0.000527 0.002259 9.631896 Chr1: 198828002-198828111 - Intron
hsa-miR-21 0.003809 0.008158 6.844031 Chr17: 57918627–57918698 + Intergenic
hsa-miR-361-5p 0.000356 0.001831 6.274443 ChrX: 85158641-85158712 - Intron
hsa-miR-1321 0.000636 0.002333 5.102661 ChrX: 85090785-85090863 + Intergenic
hsa-miR-1259 0.000025 0.000650 4.581317 Chr20: 47896847-47896957 + Intron
hsa-miR-222 0.023138 0.018584 3.929640 ChrX: 45606421-45606530 - Intergenic
hsa-miR-92b 0.001809 0.005165 3.837460 ChrX: 85090785-85090863 + Intergenic
hsa-miR-1274b 0.027961 0.020354 3.745325 Chr19: 58024375-58024441 - Intergenic
hsa-miR-129-3p 0.033490 0.021517 3.154050 Chr7: 127847925-127847996 + Intergenic
hsa-miR-1827 0.015657 0.015330 2.974803 Chr12: 100583662-100583727 + Intergenic
hsa-miR-125b-1* 0.009024 0.011043 2.731521 Chr11: 121970465-121970552 - Intron
hsa-miR-149* 0.041545 0.023727 2.409994 Chr2: 241395418-241395506 + Intron
hsa-miR-760 0.003237 0.007563 2.151964 Chr1: 94312388-94312467 + Intergenic
hsa-miR-424* 0.032166 0.021374 2.039437 ChrX: 133680644-133680741 - Exon
hsa-miR-151-3p 0.013972 0.014363 1.884168 Chr8: 141742663-141742752 - Intron
hsa-miR-193a-5p 0.023719 0.018584 1.830744 Chr17: 29887015-29887102 + Intergenic
hsa-miR-513b 0.047111 0.025222 1.777760 ChrX: 146280562-146280645 - Intergenic
hsa-miR-1224-5p 0.036530 0.022353 1.771082 Chr3: 183959193-183959277 + Intron
hsa-miR-1308 0.039140 0.023393 1.737868 ChrX: 22080259-22080312 - Intergenic
hsa-miR-423-5p 0.020774 0.018410 1.689889 Chr17: 28444097-28444190 + Intron
hsa-miR-28-3p 0.017516 0.016077 1.527087 Chr3: 188406569-188406654 + Intron
hsa-miR-24 0.032436 0.021374 1.472878 Chr9: 97848303-97848370 + Intron
Down-regulated microRNAs
hsa-miR-128 0.000356 0.001831 0.193099 Chr2: 136422967-136423048 + Intron
hsa-miR-885-5p 0.006532 0.009875 0.266100 Chr3: 10436173-10436246 - Intron
hsa-miR-99b 0.002762 0.005834 0.295771 Chr19: 52195865-52195934 + Intron
hsa-miR-204 0.011402 0.012740 0.317649 Chr9: 73424891-73425000 - Intron
hsa-miR-1296 0.006368 0.009875 0.351976 Chr10: 65132717-65132808 - Intron
hsa-miR-455-3p 0.012976 0.013895 0.361298 Chr9: 116971714-116971809 + Intron
hsa-miR-486-5p 0.006404 0.009875 0.379200 Chr8: 41517959-41518026 - Intron
hsa-miR-218 0.028405 0.020354 0.382556 Chr4: 20529898-20530007 + Intron
hsa-miR-192 0.009599 0.011213 0.411599 Chr11: 64658609–64658718 - Intergenic
hsa-miR-323-3p 0.042741 0.023879 0.510200 Chr14: 101492069-101492154 + Intergenic
hsa-miR-331-3p 0.016105 0.015330 0.515895 Chr12: 95702196-95702289 + Intergenic
hsa-miR-769-3p 0.023862 0.018584 0.530823 Chr19: 46522190-46522307 + Intergenic
hsa-miR-181c 0.021556 0.018466 0.540432 Chr19: 13985513-13985622 + Intergenic
hsa-miR-342-3p 0.008581 0.011027 0.544354 Chr14: 100575992-100576090 + Intron
hsa-miR-484 0.005505 0.009875 0.566546 Chr16: 15737151-15737229 + 3’ UTR
hsa-miR-107 0.028512 0.020354 0.609175 Chr10: 91352504-91352584 - Intron
hsa-miR-26a 0.034746 0.021780 0.641470 Chr3: 38010895-38010971 + Intron
The version of human genome reference assemble used in the study was GRCh37/hg19. * represents the opposite arm of the miRNA precursor.
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We performed cluster analysis on the microRNAs that
showed differential expression in brain tumors using Clus-
ter (version 3.0, http://bonsai.hgc.jp/~mdehoon/software/
cluster/software.htm) software. The TreeView tool (http://
jtreeview.sourceforge.net/) was used to show the results
generated by Cluster 3.0.
MicroRNA target gene prediction
The sequences of microRNAs with differential expres-
sion were obtained from the Sanger microRNA RegistryFigure 1 Cluster analysis of the 40 differentially expressed microRNA
pattern of brain tumors compared to the corresponding normal tissues.(http://www.sanger.ac.uk/software/Rfam/mirna). The se-
quences were used as query sequences to predict target
genes on the UCSC human genome sequences and
refgenes database (http://genome.ucsc.edu/). Only target
genes that were expressed in the brain were retained.
Gene Ontology (GO) analysis
We performed GO analysis on target genes of microRNAs
with differential expression based on the Gene ontology
database (http://www.geneontology.org/). Fisher’s two-side
exact test and the Chi-square test were used to classify thes. Results of cluster analysis indicate the changed microRNA expression
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culated to correct the P-value. We chose only GOs that
had a p-value of <0.05 and a FDR of < 0.05.
Pathway analysis
Pathway analysis was also performed on target genes of the
differentially expressed microRNAs based on the KEGG
database (http://www.genome.jp/kegg/). As in the GO ana-
lysis, two-side Fisher’s exact test and Chi-square test were
used to classify the KEGG pathway categories, and the false
discovery rate (FDR) was also calculated. Using a p-value




In the microarray data analysis, we investigated more than
800 microRNAs in sum and found 40 differentially
expressed microRNAs in gliomas compared to adjacent tis-
sues. Among these, 23 up-regulated and 17 down-regulated
microRNAs were involved. The information of the 40
microRNAs was summarized in Table 2. What needs illus-
tration is that miR-24 was involved in the differential ex-
pressed microRNAs because it was with low p-value and
FDR. Several recent findings suggested miR-24 played a
role in the development of gliomas [23,24]. Thus, we still
listed miR-24 in Table 2 considering the fold change
(1.472878) was very closed to the threshold set by us. Clus-
ter analysis was performed of the 40 microRNAs on the 8
brain tumors and corresponding adjacent noncancerous tis-
sues. The results are shown in Figure 1.
MicroRNA expression validation
In order to validate the microarray platform, we confirmed
the expression of four randomly selected microRNAs thatFigure 2 Validation of microRNA expression by qRT-PCR. The qRT-PCR
that the fold change of microRNAs expression level in brain tumors was clowere strongly up- or down-regulated using qRT-PCR, using
the same RNA samples that were used for the microarrays.
The expression level of miR-1259, miR-21, miR-222 and
miR-128 was identified. The fold change of each microRNA
in tumors was calculated. The qRT-PCR results showed
that miR-1259, miR-21 and miR-222 were up-regulated and
that miR-128 was down-regulated, which was in line with
the data generated from the microarray (Figure 2).
Character analysis of MicroRNA target genes
We determined the target genes of each microRNA based
on the UCSC Genome Browser Database. 2276 target genes
of up-regulated microRNAs and 2403 target genes of
down-regulated microRNAs were found to be expressed in
the human brain. We then performed GO analysis on tar-
get genes of up- and down-regulated microRNAs, respec-
tively. We found 143 significant GO categories for target
genes of up-regulated microRNAs and 168 significant GO
categories for target genes of down-regulated microRNAs.
Negative regulation of neuron apoptosis, axonogenesis,
regulation of synaptic transmission, neurotransmitter se-
cretion et al. were involved in the enriched GO categories
of target genes of up-regulated microRNAs (Figure 3A),
and the target genes of down-regulated microRNAs were
enriched in synaptic vesicle transport, positive regulation
of axon extension and positive regulation of apoptosis
et al. (Figure 3B).
Pathway analysis based on the KEGG pathway data-
base was also applied. Using a statistical method similar
to that in the GO analysis, we identified the enriched
pathways of the target genes. From our data, target
genes of up-regulated microRNAs were involved in the
ErbB signaling pathway, axon guidance, glioma, long-
term potentiation, pathways in cancer, the MAPK signaling
pathway et al. (Figure 4A). Target genes of down-regulatedassay shows the expression level of 4 microRNAs. qRT-PCR indicated
sely correlated with those detected by microarray.
Figure 3 GO categories based on biological processes for target genes of dysregulated microRNAs. (A) Target genes of the up-regulated
microRNAs were involved in negative regulation of neuron apoptosis, axonogenesis, regulation of synaptic transmission, neurotransmitter
secretion et al. (B) Target genes of the down-regulated microRNAs were involved in axonogenesis, synaptic vesicle transport, positive regulation
of axon extension et al.
Liu et al. Diagnostic Pathology 2013, 8:158 Page 6 of 10
http://www.diagnosticpathology.org/content/8/1/158microRNAs were related to N-Glycan biosynthesis, the
Wnt signaling pathway, the neurotrophin signaling path-
way, the notch signaling pathway, amino acids metabolism
et al. (Figure 4B).
A total of 165 target genes involved in both the
enriched GO categories and KEGG pathways were assem-
bled in a microRNA-gene network, in which the inter-
action between microRNAs and their corresponding
target genes was displayed. The microRNAs that had cru-
cial roles in regulating the related biological processes and
pathways were identified. Among the up-regulated micro-
RNAs, miR-24, miR-92b and miR-760 were the top three
key microRNAs in the network. The top three microRNAs
in the down-regulated microRNAs were miR-128, miR-218
and miR-26a. As for target genes, CACNA1E (Voltage-dependent R-type calcium channel subunit alpha-1E), FOX
O3 (Forkhead box protein O3) and STX6 (Syntaxin-6)
were the top three key genes in the microRNA-gene net-
work (Figure 5).Discussion
In the present study we used a microRNA microarray assay
to study the differential expression pattern of microRNA in
pediatric gliomas and the matched adjacent noncancerous
tissues. Among the microRNAs detected in the microarray,
we identified 40 microRNAs showing significantly higher
or lower expression levels in tumors compared to the
matched normal tissues. Results of GO analysis and KEGG
pathway analysis suggested that target genes were closely
Figure 4 KEGG pathway analysis for target genes of dysregulated microRNAs. (A) Target genes of up-regulated microRNAs were involved
in the ErbB signaling pathway, axon guidance, glioma, long-term potentiation, the MAPK signaling pathway et al. (B) Target genes of down-
regulated microRNAs were related to the neurotrophin signaling pathway, the notch signaling pathway, amino acids metabolism et al.
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biological processes and signaling pathways.
Some of the microRNAs that showed differential ex-
pression between brain tumors and normal tissues in
our study had previously been studied or found to be as-
sociated with gliomas, including pediatric gliomas. MiR-
21, which was discovered to be upregulated by us, was
also found and validated to be with increased expression
in pediatric pilocytic astrocytoma (PA), a World Health
Organization grade I pediatric glioma, in the study of
Ho CY et al. [25]. Overexpression of miR-222 in gliomaswas also observed by the research of Li Q et al. [26].
They proved that miR-222 could regulate Wnt/β-catenin
signaling pathway and promote glioma genesis by using
RNA interference and western blot technology. Further-
more, downregulation of miR-204, which was found to be
associated with gliomas in our study, was also proved to
contribute to glioma migration by targeting the migration-
promoting receptor EphB2 [27]. In the present study miR-
218 was discovered to be with decreased expression in
pediatric gliomas, indicating the reverse relationship be-
tween miR-218 expression and development of gliomas.
Figure 5 MicroRNA-gene network analysis. Target genes of the dysregulated microRNAs are assembled in the network according to their
microRNA status. The circles represent genes that were involved in both the enriched GO categories and KEGG pathways. The squares represent
the dysregulated microRNAs (red for those up-regulated and blue for those down-regulated). Green lines mark the interactions between
microRNAs and corresponding target genes.
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They found that upregulation of miR-218 reduced the mi-
gration, invasion and proliferation of glioma cells dramat-
ically by regulating a wide range of genes and pathways. A
new target gene of miR-218, which was noticed to be
down-regulated in glioma in our study, has recently been
found in the study of Shi ZM et al. [29]. They identified
p70S6K1 as a novel direct target of miR-128 and
overexpression of p70S6K1 can partly rescue the inhibitory
effect of miR-128 in the glioma cells. This result further
confirms our findings.
As expected, some of the microRNAs that showed dif-
ferential expression in gliomas in our data were novel.
There is little evidence about the relationship between
miR-1321, miR-513b, miR-769-3p and cancer genesis.
In addition, the upregulated microRNAs including miR-
424*, miR-760, miR-513b, miR-361-5p, miR-1259, miR-363,
miR-199a, miR-1827, miR-423-5p, miR-1308, miR-1274,
miR-1224, miR-513b and the downregulated microRNAs
including miR-885, miR-769, miR-1296, miR-192, miR-331-
3p, miR-484, miR-99b were found to be related with gli-
omas for the first time. This may provide new clues for
gliomas research.
Aberrant expression of microRNAs may contribute to
the induction of pediatric gliomas by regulating genes in-
volved in nervous system-related and tumor-related bio-
logical processes and signaling pathways. According to theresult of GO analysis, the target genes were involved in
negative regulation of neuron apoptosis, axonogenesis,
regulation of synaptic transmission, neurotransmitter secre-
tion and synaptic vesicle transport et al.. These biological
processes are crucial for maintaining normal functioning
of the nervous system. Alteration of the processes induced
by aberrant expression of certain microRNAs may favor
glioma-genesis. As for biological pathways, several cancer-
related pathways, including glioma, endometrial cancer, the
TGF-beta signaling pathway, the MAPK signaling pathway,
the wnt signaling pathway and the notch signaling pathway
et al. were among the enriched pathways of the target
genes. TGF-beta signaling has long been considered to con-
tribute to glioma pathogenesis by direct support of tumor
growth, self-renewal of glioma initiating stem cells and the
inhibiting of anti-tumor immunity [30]. Wnt signaling and
MAPK signaling also play significant roles in almost all
kinds of tumors, including glioma [31]. In recent studies,
notch signaling has been proved to be dysregulated in brain
tumors and to contribute to the malignant potential of
these tumors [32]. Peng Xu et al. found out the different
roles of Notch1 and Notch2. They proved that both up-
regulating of Notch1 and knocking down Notch2 had the
effect of suppressing glioma cell growth and invasion as
well as inducing apoptosis [33].
In conclusion, we investigated the changed expression
patterns of microRNAs in pediatric gliomas and identified
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genes in brain tumor pathology. However, due to the limi-
tation of the microarray assay, only 866 known human
microRNAs were detected. The role of more microRNAs
in brain tumors needs to be investigated using more ad-
vanced techniques, such as second-generation sequencing
and higher capacity microarrays. The present study does
at least provide new insights into pediatric brain tumor
biology and may assist in finding new diagnostic and
therapeutic tools for these tumors.
Conclusions
The changed expression pattern of microRNAs in pediatric
gliomas was investigated and it may assist in finding new
diagnostic and therapeutic strategies for these tumors. The
specific microRNA expression pattern provides biomarkers
for the diagnosis, staging and prognosis of gliomas. The
differential expressed microRNA may also provide targets
for drug development. MicroRNA mimics and inhibitors
can strengthen and weaken the regulation of target genes
respectively and may be novel antitumor candidates.
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